ATTAIN-2: Orforglipron Phase 3 trial (NCT05872620)
A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)
At a glance
- Phase
- Phase 3
- Status
- Completed
- Enrolment
- 1,613
- actual
- Start
- 5 Jun 2023 (actual)
- Primary completion
- 8 Aug 2025 (actual)
- Sponsor
- Eli Lilly and Company
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Placebo | Placebo comparator | Drug: Placebo | Participants received matching placebo capsule orally once daily (QD). Treatment was initiated with placebo corresponding to 1 milligram (mg) equivalent to Orforglipron, with dose escalation every 4 weeks to maintain blinding, and was continued through Week 72, unless dose modification was required. |
| 6 mg Orforglipron QD | Experimental | Drug: Orforglipron | Participants received oral orforglipron capsule once daily. Treatment was initiated at 1 mg once daily, with dose escalation every 4 weeks to a target dose of 6 mg, which was maintained through Week 72, unless dose modification was required. |
| 12 mg Orforglipron QD | Experimental | Drug: Orforglipron | Participants received oral orforglipron capsule once daily. Treatment was initiated at 1 mg once daily, with dose escalation every 4 weeks to a target dose of 12 mg, which was maintained through Week 72, unless dose modification was required. |
| 36 mg Orforglipron QD | Experimental | Drug: Orforglipron | Participants received oral orforglipron capsule once daily. Treatment was initiated at 1 mg once daily, with dose escalation every 4 weeks to a target dose of 36 mg, which was maintained through Week 72, unless dose modification was required. |
Primary endpoint
| Measure | Time frame |
|---|---|
| Percent Change From Baseline in Body Weight | Baseline, Week 72 |
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Percentage of Participants Who Achieved With Greater Than or Equal to (≥) 5% Body Weight Reduction From Baseline | Baseline to Week 72 |
| Percentage of Participants Who Achieved ≥10% Body Weight Reduction From Baseline | Baseline to Week 72 |
| Percentage of Participants Who Achieved ≥15% Body Weight Reduction From Baseline | Baseline to Week 72 |
| Change From Baseline in Waist Circumference | Baseline, Week 72 |
| Change From Baseline in Hemoglobin A1c (HbA1c) % | Baseline, Week 72 |
| Change From Baseline in Fasting Serum Glucose (FSG) | Baseline, Week 72 |
| Percentage of Participants Who Achieved Hemoglobin A1c (HbA1c) Target Value (<6.5%) | Baseline to Week 72 |
| Percentage of Participants Who Achieved Hemoglobin A1c (HbA1c) Target Value (<7.0%) | Baseline to Week 72 |
| Change From Baseline in Systolic Blood Pressure (SBP) (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) | Baseline, Week 72 |
| Change From Baseline in Diastolic Blood Pressure (DBP) (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) | Baseline, Week 72 |
| Percent Change From Baseline in Fasting Insulin | Baseline, Week 72 |
| Percent Change From Baseline in Non-High-Density Lipoprotein (Non-HDL) Cholesterol (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) | Baseline, Week 72 |
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- Not stated
Results
Results are posted on the registry. Open the ClinicalTrials.gov record for NCT05872620.
ATTAIN-2 in adults with obesity and type 2 diabetes
Adults with a BMI of 27 or higher and HbA1c of 7-10% were randomised 1:1:1:2 to orforglipron 6, 12 or 36 mg or placebo once daily.[2]
Weight changed by -5.1%, -7.0% and -9.6% at 6, 12 and 36 mg against -2.5% on placebo (all p<0.0001).[2]
Discontinuation due to adverse events was 6.1-9.9% on orforglipron against 4.1% on placebo.[2]
Ten deaths were reported during the study, six on orforglipron and four on placebo, and investigators judged most unrelated to treatment.[2]
Sources
- 1A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)ClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
- 2Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.Lancet (London, England) · 2026PMID 41275875Accessed 2 Oct 2026
Found an error? Report a correction.